Literature DB >> 16854549

MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.

Hans-Joachim Schwarzmaier1, Frank Eickmeyer, Wernholt von Tempelhoff, Volkhard Ulrich Fiedler, Hendrik Niehoff, Slif Dagobert Ulrich, Qin Yang, Frank Ulrich.   

Abstract

We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent glioblastoma multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (<5 months) or after chemotherapy (temozolomide: 5.4-7.1 months). We conclude that cytoreduction by laser irradiation might be a promising option for patients suffering from recurrent glioblastoma multiforme. In addition, the data indicate the presence of a substantial learning curve. Future work should optimize the therapeutic regimen and evaluate this treatment approach in controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16854549     DOI: 10.1016/j.ejrad.2006.05.010

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  42 in total

1.  Quantitative comparison of thermal dose models in normal canine brain.

Authors:  Joshua P Yung; Anil Shetty; Andrew Elliott; Jeffrey S Weinberg; Roger J McNichols; Ashok Gowda; John D Hazle; R Jason Stafford
Journal:  Med Phys       Date:  2010-10       Impact factor: 4.071

Review 2.  Laser induced thermal therapy (LITT) for pediatric brain tumors: case-based review.

Authors:  Margaret Riordan; Zulma Tovar-Spinoza
Journal:  Transl Pediatr       Date:  2014-07

3.  Design and initial evaluation of a treatment planning software system for MRI-guided laser ablation in the brain.

Authors:  E Yeniaras; D T Fuentes; S J Fahrenholtz; J S Weinberg; F Maier; J D Hazle; R J Stafford
Journal:  Int J Comput Assist Radiol Surg       Date:  2013-10-05       Impact factor: 2.924

4.  Preclinical assessment of a 980-nm diode laser ablation system in a large animal tumor model.

Authors:  Kamran Ahrar; Ashok Gowda; Sanaz Javadi; Agatha Borne; Matthew Fox; Roger McNichols; Judy U Ahrar; Clifton Stephens; R Jason Stafford
Journal:  J Vasc Interv Radiol       Date:  2010-04       Impact factor: 3.464

Review 5.  Image-guided thermal ablation with MR-based thermometry.

Authors:  Mingming Zhu; Ziqi Sun; Chin K Ng
Journal:  Quant Imaging Med Surg       Date:  2017-06

Review 6.  Surgical treatment of hypothalamic hamartomas.

Authors:  Pierre Bourdillon; S Ferrand-Sorbet; C Apra; M Chipaux; E Raffo; S Rosenberg; C Bulteau; N Dorison; O Bekaert; V Dinkelacker; C Le Guérinel; M Fohlen; G Dorfmüller
Journal:  Neurosurg Rev       Date:  2020-04-21       Impact factor: 3.042

7.  Safety and effectiveness of stereotactic laser ablation for epileptogenic cerebral cavernous malformations.

Authors:  Jon T Willie; James G Malcolm; Matthew A Stern; Lindsay O Lowder; Stewart G Neill; Brian T Cabaniss; Daniel L Drane; Robert E Gross
Journal:  Epilepsia       Date:  2019-01-17       Impact factor: 5.864

Review 8.  Maximizing safe resection of low- and high-grade glioma.

Authors:  Shawn L Hervey-Jumper; Mitchel S Berger
Journal:  J Neurooncol       Date:  2016-05-12       Impact factor: 4.130

Review 9.  Focal therapy in prostate cancer: modalities, findings and future considerations.

Authors:  Uri Lindner; John Trachtenberg; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

Review 10.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.